Madeline Ducate

Pharm-Olam International started operations in 1994 with the premise of delivering cost effective, quick-to-market clinical services in the emerging markets of Central and Eastern Europe. Since then, POI has expanded its services to more than 40 countries, including: North America, Western Europe, Central & Eastern Europe, Latin America, India, and South Africa. Today, POI has one of the largest global footprints of any CRO. They are committed to establishing and maintaining the industry's strongest multi-national presence. Its monitors have the most extensive knowledge of local and regional customs and sites across a broad range of therapeutic areas. POI has an entirely different model than other CROs- they call it global decentralization. The success of this model has been proven time and again.

Pharmaceutical Product Development LLC engages in the operation of a global contract research organization, which provides drug development, laboratory and lifecycle management services. It offers adaptive trial design, bio analytical lab, bio similar development, biostatistics, GMP lab, clinical supplies, trial monitoring, CMC regulatory, data management, dental pain clinic, real-world outcomes, site intelligence and activation, central lab, global regulatory affairs, IRT systems, late stage research, medical communications, device and diagnostics, medical writing, nonclinical development and regulatory consulting and intelligence, regulatory development, innovation and vaccine sciences. The company was founded by Fredric N. Eshelman in 1985 and is headquartered in Wilmington, NC.